Ratings Life Science REIT plc

Equities

LABS

GB00BP5X4Q29

Real-time Estimate Cboe Europe Other stock markets 12:35:50 15/05/2024 BST			5-day change	1st Jan Change
37.85 ^GBX	-0.66%		-5.50%	-40.19%

03-27	Jefferies Downgrades Life Science REIT to Hold from Buy, Cuts PT	MT
03-27	Sorted renews M&S deal; Tribe completes drill build	AN

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The company's attractive earnings multiples are brought to light by a P/E ratio at 12.29 for the current year.
This company will be of major interest to investors in search of a high dividend stock.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Residential REITs

	1st Jan change	Capi.	ESG Refinitiv
LIFE SCIENCE REIT PLC	-39.72%	168M	-
AVALONBAY COMMUNITIES, INC.	+5.49%	28.04B	A-
EQUITY RESIDENTIAL	+10.19%	25.54B	B
INVITATION HOMES INC.	+2.55%	21.43B	B-
ESSEX PROPERTY TRUST, INC.	+6.87%	17.01B	B+
MID-AMERICA APARTMENT COMMUNITY, INC.	+1.76%	15.98B	B
SUN COMMUNITIES, INC.	-12.13%	14.64B	C
AMERICAN HOMES 4 RENT	+0.31%	13.21B	B
UDR INC.	+2.82%	12.96B	B
EQUITY LIFESTYLE PROPERTIES, INC.	-11.70%	11.62B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes